{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T10:20:46Z","timestamp":1702549246358},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1670","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy), which was approved by the FDA in 2021 for chronic weight management in adults,1 has now been approved for chronic weight management in children \u226512 years old with an initial BMI in the \u226595th percentile for age and sex.Semaglutide is also available as Ozempic and Rybelsus for treatment of type 2 diabetes in adults.<\/jats:p>","DOI":"10.58347\/tml.2023.1670d","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T16:01:41Z","timestamp":1678982501000},"page":"31-32","source":"Crossref","is-referenced-by-count":1,"title":["In Brief: Semaglutide (Wegovy) for Weight Loss in Children"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,2,20]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T16:01:41Z","timestamp":1678982501000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1670d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":0,"journal-issue":{"issue":"1670","published-online":{"date-parts":[[2023,2,20]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1670d","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}